Jump to content

Vaccine Research


RandyW

Recommended Posts

LUNG CANCER VACCINES

Lung cancer affects more than 1.2 million patients a year, with around 500,000 in the US, Europe and Japan. Non-small cell lung cancer is one of the leading causes of death, resulting in the worst survival rates for all cancers and killing more patients than breast, colon and prostate cancer together.

Answering key business questions

-Merck and GSK are fighting for the lion's share of the as yet unexploited multi billion US$ cervical cancer vaccine market. What differentiates the two products and how might this affect their sales?

-Dendreon has an open market with its prostate cancer vaccine Provenge. But does it have the sales experience and marketing muscle to achieve sales estimated at US$799 million in 2011?

-Will GSK/Avant Immunotherapuetics' monovalent vaccine derived from human rotavirus strain Rotarix 2-dose regimen see off competition from Merck's Rotateq in the US$2 billion rotavirus market?

-In a sector free of competition, Merck faces considerable marketing challenges for its Herpes Zoster vaccine Zostamax. What are they?

This chapter covers:

- Current Market Size

- Addressable Patient Population

- Current Treatments

- Sales Drivers

- Sales Breakers

- Future Treatments - Early Stage

- Market Dynamics - Winners and Losers

- Key launches to 2011

- Competitor Ratio Analysis - Products

- Competitor Ratio Analysis - Companies

For more information visit http://www.researchandmarkets.com/reports/c40622

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.